Related Experiment Videos

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses

S I Abrams1, S F Stanziale, S D Lunin

  • 1Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892-1750, USA.

Insights

Mutant ras peptides can trigger CD8+ cytotoxic T lymphocytes (CTL) to target tumor cells. This study shows a specific mutant K-ras peptide induces anti-ras CTL, demonstrating potential for cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Mutant ras p21 proteins possess unique sequences distinct from normal ras, offering potential T cell recognition epitopes.
  • Tumor cells expressing mutant ras oncoproteins are targets for immune surveillance.

Purpose of the Study:

  • To investigate the capacity of a mutant K-ras 9-mer peptide to induce CD8+ cytotoxic T lymphocytes (CTL) in vivo.
  • To assess the immunogenicity and specificity of a mutant ras peptide for anti-tumor immune responses.

Main Methods:

  • A mutant K-ras 9-mer peptide (positions 4-12, Gly to Val substitution at codon 12) was designed based on MHC class I binding motifs.
  • Functional binding to H-2Kd was assessed using a peptide inhibition assay.
  • An anti-ras CD8+ T cell line was generated from immunized mice and tested for peptide-specific cytotoxicity against tumor targets.

Main Results:

  • The mutant ras4-12(V12) peptide demonstrated functional binding to H-2Kd, unlike the normal ras4-12(G12) peptide.
  • An H-2Kd-restricted, peptide-specific CD8+ T cell line was established, mediating lysis of syngeneic tumor cells.
  • These CTL specifically recognized and lysed a syngeneic tumor line engineered to express the mutant K-ras oncogene.

Conclusions:

  • Mutant ras p21 at codon 12 contains a peptide sequence capable of specific binding to murine MHC class I molecules.
  • The mutant ras peptide is immunogenic, inducing antigen-specific CD8+ CTL.
  • These CTL can effectively lyse tumor cells expressing the endogenous mutant K-ras oncogene, highlighting a potential therapeutic strategy.

Related Concept Videos